At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
Zanubrutinibdrug
Likely dose
Zanubrutinib 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Single Arm, Multicenter, Open-label Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Zanubrutinib for Diffuse Large B-cell Lymphoma. Completed, enrolled 41 participants across 11 sites.
Detailed Summary
Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 2 years), safety follow-up (30 days); survival follow-up until data cutoff for final analysis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B-cell Lymphoma
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartJun 2017
Primary CompletionMay 2019
Study CompletionSep 2020
TodayJul 2026
First PostedMay 9, 2017
Enrollment StartJun 30, 2017
Primary CompletionMay 24, 2019
Study CompletionSep 3, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.1 years ago
Interventions
Zanubrutinibdrug
Administered at a dose of 160 mg BID orally.